Dr. Masataka Kusunoki
My Social Links

Dr. Masataka Kusunoki

Professor
Nagoya University, Japan

Highest Degree
Ph.D. in Clinical Immunology from Aichi Medical University, Japan

Share this Profile

Area of Interest:

Biomedical Sciences
100%
Clinical Practice
62%
Gerontology
90%
Metabolism
75%
Medecine
55%

Research Publications in Numbers

Books
0
Chapters
0
Articles
0
Abstracts
0

Selected Publications

  1. Sato, D., K. Oda, M. Kusunoki, A. Nishina and K. Takahashi et al., 2016. PPARγ activation alters fatty acid composition in adipose triglyceride, in addition to proliferation of small adipocytes, in insulin resistant high-fat fed rats. Eur. J. Pharmacol., 773: 71-77.
    CrossRef  |  Direct Link  |  
  2. Kusunoki, M., Y. Natsume, D. Sato, H. Tsutsui and T. Miyata et al., 2016. Luseogliflozin, a sodium glucose co-transporter 2 inhibitor, alleviates hepatic impairment in Japanese patients with type 2 diabetes. Drug Res., 66: 603-606.
    CrossRef  |  PubMed  |  Direct Link  |  
  3. Kusunoki, M., D. Sato, T. Nakamura, Y. Oshida and H. Tsutsui et al., 2016. The beneficial effects of the DPP-4 inhibitor alogliptin on hemoglobin A1c and serum lipids in Japanese patients with type 2 diabetes. Drug Res., 66: 18-22.
    CrossRef  |  PubMed  |  Direct Link  |  
  4. Sato, D., M. Kusunoki, G. Shinzawa, Z. Feng, A. Nishina and T. Nakamura, 2015. Effects of aldose reductase inhibitor on microneurographically assessed peripheral sympathetic nerve activity in rats. Autonomic Neurosci.: Basic Clin., 193: 69-73.
    CrossRef  |  Direct Link  |  
  5. Kusunoki, M., D. Sato, T. Nakamura, Y. Oshida and H. Tsutsui et al., 2015. DPP-4 inhibitor teneligliptin improves insulin resistance and serum lipid profile in Japanese patients with type 2 diabetes. Drug Res., 65: 532-534.
    CrossRef  |  PubMed  |  Direct Link  |  
  6. Kusunoki, M., D. Sato, K. Tsutsumi, H. Tsutsui, T. Nakamura and Y. Oshida, 2015. Black soybean extract improves lipid profiles in fenofibrate-treated type 2 diabetics with postprandial hyperlipidemia. J. Med. Food, 18: 615-618.
    CrossRef  |  Direct Link  |  
  7. Chen, T., M. Kusunoki, D. Sato, H. Tsutsui, T. Nakamura, T. Miyata and Y. Oshida, 2013. Clinical effect of addition of beraprost sodium to pioglitazone treatment on the blood glucose levels in patients with type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes, 121: 624-627.
    CrossRef  |  PubMed  |  Direct Link  |  
  8. Sato, D., T. Nakamura, K. Tsutsumi, G. Shinzawa and T. Karimata et al., 2012. Site dependency of fatty acid composition in adipose triacylglycerol in rats and its absence as a result of high-fat feeding. Metab.: Clin. Exp., 61: 92-98.
    CrossRef  |  Direct Link  |  
  9. Kusunoki, M., K. Tsutsumi, D. Sato, A. Nakamura and S. Habu et al., 2011. Activation of lipoprotein lipase increases serum high density lipoprotein 2 cholesterol and enlarges high density lipoprotein 2 particles in rats. Eur. J. Pharmacol., 668: 337-339.
    CrossRef  |  Direct Link  |  
  10. Kusunoki, M., K. Tsutsumi, D. Sato, A. Nakamura and S. Habu et al., 2011. Pioglitazone-induced body weight gain is prevented by combined administration with the lipoprotein lipase activator NO-1886. Eur. J. Pharmacol., 668: 486-491.
    CrossRef  |  Direct Link  |  
  11. Kusunoki, M., K. Tsutsumi, K. Iwata, W. Yin and T. Nakamura et al., 2005. NO-1886 (ibrolipim), a lipoprotein lipase activator, increases the expression of uncoupling protein 3 in skeletal muscle and suppresses fat accumulation in high-fat diet-induced obesity in rats. Metab.: Clin. Exp., 54: 1587-1592.
    CrossRef  |  Direct Link  |  
  12. Kusunoki, M., K. Tsutsumi, Y. Inoue, T. Hara and T. Miyata et al., 2004. Lipoprotein lipase activator NO-1886 improves fatty liver caused by high-fat feeding in streptozotocin-induced diabetic rats. Metab.: Clin. Exp., 53: 260-263.
    CrossRef  |  Direct Link  |  
  13. Kusunoki, M., K. Tsutsumi, T. Hara, H. Ogawa and T. Nakamura et al., 2003. Ethyl icosapentate (omega-3 fatty acid) causes accumulation of lipids in skeletal muscle but suppresses insulin resistance in OLETF rats. Metabolism, 52: 30-34.
    CrossRef  |  Direct Link  |  
  14. Kusunoki, M., K. Tsutsumi, T. Hara, H. Ogawa and T. Nakamura et al., 2002. Correlation between lipid and glycogen contents in liver and insulin resistance in high-fat [ndash] fed rats treated with the lipoprotein lipase activator NO-1886. Metab.: Clin. Exp., 51: 792-795.
    CrossRef  |  Direct Link  |  
  15. Kusunoki, M., K. Tsutsumi, T. Hara, H. Ogawa and T. Nakamura et al., 2002. A lipoprotein lipase activator, NO-1886 prevents impaired endothelium-dependent relaxation of aorta caused by exercise in aged rats. Exp. Gerontol., 37: 891-896.
    CrossRef  |  Direct Link  |  
  16. Kusunoki, M., T. Hara, K. Tsutsumi, T. Nakamura and T. Miyata et al., 2000. The lipoprotein lipase activator, NO-1886, suppresses fat accumulation and insulin resistance in rats fed a high-fat diet. Diabetologia, 43: 875-880.
    CrossRef  |  Direct Link  |  
  17. Kusunoki, M., G.J. Cooney, T. Hara and L.H. Storlien, 1995. Amelioration of high-fat feeding-induced insulin resistance in skeletal muscle with the antiglucocorticoid RU486. Diabetes, 44: 718-720.
    CrossRef  |  Direct Link  |  
  18. Kusunoki, M., L.H. Storlien, J. MacDessi, N.D. Oakes, C. Kennedy, D.J. Chisholm and E.W. Kraegen, 1993. Muscle glucose uptake during and after exercise is normal in insulin-resistant rats. Am. J. Physiol.-Endocrinol. Metab., 264: E167-E172.
    CrossRef  |  Direct Link  |  
  19. Kusunoki, M., Y. Oshida, A. Iguchi, T. Iida and T. Suga et al., 1992. Influence of sympatho-adrenal system on insulin sensitivity using the euglycemic clamp technique. Diabetes Res. Clin. Pract., 17: 125-131.
    CrossRef  |  Direct Link  |